The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study

Elevated low-density lipoprotein (LDL) cholesterol is one of the leading causes of cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce LDL cholesterol levels with subsequent reductions in cardiovascular morbidity. Elevated aldosterone levels are also assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Izkhakov, Elena, Shacham, Yacov, Serebro, Merav, Yaish, Iris, Marcus, Yonit, Shefer, Gabi, Tordjman, Karen, Greenman, Yona, Stern, Naftali, Ziv-Baran, Tomer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201266/
https://www.ncbi.nlm.nih.gov/pubmed/34198795
http://dx.doi.org/10.3390/jcm10112504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201266/
https://www.ncbi.nlm.nih.gov/pubmed/34198795
http://dx.doi.org/10.3390/jcm10112504

Ejemplares similares